OneSkin

OneSkin is a biotechnology company operating in the longevity and skincare market, founded in 2016 by four female Brazilian scientists: Dr. Carolina Reis Oliveira (CEO), Dr. Alessandra Zonari (CSO), Dr. Mariana Boroni, and Dr. Juliana Carvalho. The founders, who met during their doctoral studies in Brazil, leveraged their collective expertise in immunology, stem cell biology, skin regeneration, and bioinformatics to establish the company. Their journey began not with the intent to create a skincare product, but to test the efficacy of existing anti-aging products on 3D human skin models they were growing in their lab. Discovering that many products were ineffective and some even harmful at a cellular level, they pivoted to develop molecules that could target the root causes of skin aging.

The company's core business revolves around its proprietary peptide, OS-01, developed after screening over 900 peptides. This peptide is the first scientifically shown to reduce skin's biological age by targeting cellular senescence—the accumulation of aged, dysfunctional cells that contribute to wrinkles and loss of firmness. The OS-01 peptide works by preventing this accumulation, supporting cellular repair, and promoting markers associated with collagen and hyaluronic acid production. Lab studies on human skin models demonstrated that the OS-01 peptide could increase epidermal thickness by up to 28% and reduce the skin's biological age by approximately 2.5 years in just five days.

OneSkin's business model is primarily direct-to-consumer (DTC) through its website, with a strong emphasis on a subscription model that accounts for two-thirds of its online sales. The company also distributes its products through Amazon, which constitutes about 10% of sales, and is expanding into wholesale channels to reach professionals like dermatologists and aestheticians. Their product line, which includes topical supplements for the face, body, eyes, lips, and hair, is priced in the premium segment, ranging from $45 to $120. The company's primary markets are the United States, Canada, and the United Kingdom. Its customer base is mainly Gen X and millennial women, but men also represent a significant 20% of its clientele.

Financially, OneSkin has demonstrated significant growth, securing a total of $40.6 million in funding over five rounds. A notable Series A round, led by Selva Ventures with participation from Unilever Ventures, raised $7 million, bringing the company's total funding to $20 million at that time. A subsequent Series B round in May 2025 raised an additional $20.4 million. While the company is profitable, its CEO noted that 2024 revenue estimates of under $10 million were low, stating the company operates at a Series B level in terms of revenue. OneSkin is focused on continued international expansion, new product development, and advancing clinical studies to further validate its technology. Keywords: skin longevity, senotherapeutics, OS-01 peptide, cellular senescence, biotechnology skincare, direct-to-consumer beauty, anti-aging science, female-founded startup, Carolina Reis Oliveira, skin biological age, tissue engineering, science-backed skincare, collagen production, skincare clinical trials, IndieBio accelerator, Selva Ventures, Unilever Ventures, premium skincare, skin barrier function, subscription beauty